$AGRX They say 14 to 1 abstain, but there also was a no. I don't know if FDA typically goes based on stats or need/desire for more options. There were questions about efficacy and why half the participants in the study did not complete it. I'm bullish, because I want this thing to take off, but the meeting didn't sound like a homerun. At the end they asked the FDA if they had any comments or questions and they just stayed silent. Maybe that's normal, first one I've seen.